Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 9/20 | 0.37 |
| ▸ | KIT | P10721 | 6/20 | 0.37 |
| ▸ | FLT3 | P36888 | 5/20 | 0.37 |
| ▸ | JAK1 | P23458 | 2/20 | 0.35 |
| ▸ | TYK2 | P29597 | 2/20 | 0.35 |
| ▸ | JAK3 | P52333 | 2/20 | 0.35 |
| ▸ | ILK | Q13418 | 3/20 | 0.35 |
| ▸ | LCK | P06239 | 4/20 | 0.34 |
| ▸ | CSF1R | P07333 | 4/20 | 0.34 |
| ▸ | FLT1 | P17948 | 4/20 | 0.34 |
| ▸ | LYN | P07948 | 3/20 | 0.34 |
| ▸ | SRC | P12931 | 3/20 | 0.34 |
| ▸ | FLT4 | P35916 | 3/20 | 0.34 |
| ▸ | BLK | P51451 | 3/20 | 0.34 |
| ▸ | FYN | P06241 | 2/20 | 0.34 |
| ▸ | CDK19 | Q9BWU1 | 2/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | IKBKB | O14920 | 2/20 | 0.32 |
| ▸ | AURKA | O14965 | 1/20 | 0.31 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25669046 | 0.83 | KIT (0.35) | KDRKITFLT3JAK1TYK2 | |
| SCHEMBL25667661 | 0.81 | ADORA2A (0.33) | ADORA2AADORA2B | |
| SCHEMBL22349086 | 0.80 | KDR (0.37) | KDRKITFLT3JAK1TYK2 | |
| SCHEMBL22328041 | 0.80 | KDR (0.34) | KDRKITFLT3JAK1TYK2 | |
| SCHEMBL25696132 | 0.80 | KDR (0.34) | KDRKITFLT3JAK1TYK2 | |
| SCHEMBL25669048 | 0.79 | PDPK1 (0.40) | KDRKITFLT3JAK1TYK2 | |
| SCHEMBL25672741 | 0.69 | REN (0.33) | — | |
| SCHEMBL11745813 | 0.67 | KDR (0.42) | KDRKITFLT3JAK1TYK2 | |
| SCHEMBL25696139 | 0.67 | — | — | |
| SCHEMBL786095 | 0.66 | GPR84 (0.40) | KDRFLT3ILKLCKCSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4328229-A2 | SUBSTITUTED HETEROCYCLIC FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | Genfleet Therapeutics (Shanghai) Inc. (CN) | 2024-02-28 | — | — | EP | disclosed |
| US-20230203018-A1 | COVALENT INHIBITORS OF KRAS | ARAXES PHARMA LLC (US) | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203018-A1 | COVALENT INHIBITORS OF KRAS | KRAS, NRAS, HRAS | KDR 2074/4885KIT 3570/4885FLT3 714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.